Elanco Animal Health beats Q4 revenue estimates, raises FY innovation revenue target

Overview

• Animal health company's Q4 revenue rose 12%, beating analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

Outlook

• Elanco projects 2026 revenue of $4.95 bln to $5.02 bln

• Company expects 2026 adjusted EBITDA of $955 mln to $985 mln

• Elanco raises 2026 innovation revenue target to $1.15 bln

Result Drivers

• NEW PRODUCTS - Revenue growth driven by new products like Credelio Quattro and Zenrelia, contributing to pet health sector

• FARM ANIMAL SALES - Growth in farm animal revenue supported by Experior in cattle and strong poultry sales

• INNOVATION PIPELINE - Approval of Befrena and strong innovation momentum cited as growth drivers

Company press release: ID:nPnbDd19Ra

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Elanco Animal Health Inc is $27.00, about 9.1% above its February 23 closing price of $24.75

• The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.